Spring Bioscience Offers PTEN Antibody Optimized for IHC; A New Option for Research in Critical Cancer Pathway

Comparison studies show SP218 clone provides superior accuracy, specificity on PTEN loss

PLEASANTON, CA, September 4, 2013 - Spring Bioscience, Inc. (Spring) today announced a new addition to its portfolio of high-value rabbit monoclonal antibodies for cancer research. Spring now offers the Anti-PTEN (SP218) Rabbit Monoclonal Antibody, a highly-sensitive clone developed specifically for immunohistochemistry (IHC) applications. PTEN is a tumor-suppressing protein; loss of expression is frequently found in solid tumors such as prostate and colon cancer.

Accurate and specific assessments of PTEN loss are critical given the PI3K/PTEN pathway’s major role in tumorigenesis. SP218 meets this demand as a new option within the limited selection of PTEN antibodies, addressing the need for a product optimized for IHC on FFPE tissue.

“Spring Bioscience was founded by scientists to serve the immunohistochemistry market, developing ‘best in class’ rabbit monoclonal antibodies for IHC research,” said Spring General Manager Michael Rivers. “With SP218, we’re seeking to set a new gold standard – an extremely sensitive, specific clone that will allow researchers and pathologists to interpret PTEN status with utmost confidence.”

Internal comparison studies confirm that SP218 provides researchers with more accurate interpretations of PTEN expression. Samples for more than 100 cases of primary prostate and colon cancer showed a 100% concordance rate for PTEN loss among SP218 and the leading commercially-available PTEN antibodies. The competitor clones exhibited some non-specific staining in IHC testing, while SP218 – engineered for IHC – demonstrated specific staining in cells with normal PTEN, but negative in PTEN-loss cancer cells.

“Our results show that SP218 produces a clear signal in the carcinoma and the stroma, with less background than the competitor clones,” noted Spring Bioscience Pathologist Dr. Zhiming Liao. “Antibodies can perform well with Western Blot, but those results may not translate to IHC on paraffin-embedded samples. SP218 is producing specific, accurate results for the detection of PTEN loss across the board.”

SP218’s robust and consistent performance with IHC analysis is particularly important given PTEN’s prognostic value and potential as a companion diagnostic biomarker. Spring Bioscience is owned by Ventana Medical Systems, Inc., a member of the Roche group, and serves as an antibody center of excellence in Roche’s development of companion diagnostics to advance the goal of personalized healthcare.

“As researchers work towards customized diagnostics and therapies for solid tumor cancers, they demand reliable, reproducible analysis,” added Rivers. “Spring is known for our quality development practices, delivering a consistent supply of highly-specific antibodies. SP218 meets our high standards in assessing PTEN loss.”

The Anti-PTEN (SP218) Rabbit Monoclonal Antibody is available in 0.1, 0.5, and 1.0mL concentrate configurations, as well as 7.0mL ready-to-use. Recommended staining protocols are available for manual, semi-automated and Ventana Discovery XT platforms, for decreased assay development times.

To order or request additional information on SP218, call (800) 787-6896 or (925) 474-8440. Orders can also be submitted via e-mail at [email protected], with technical detail available through [email protected].

About Spring Bioscience

Spring Bioscience, Inc. (Spring) is a leading developer of rabbit monoclonal antibodies, engineered for immunoshistochemistry (IHC) and other applications in tissue-based cancer research. Founded by scientists with a primary focus on IHC, Spring has developed a proprietary menu of highly-sensitive antibodies (SP clones) that yield superior specificity and consistency in research and clinical practice. Spring is committed to high-quality development standards, and also offers a portfolio of advanced detection and other complementary products for reliable, reproducible assessments of protein expression.

Spring Bioscience was acquired by Ventana Medical Systems, now a member of the Roche Group, in 2007. As an antibody center of excellence for Roche with strong pharmaceutical partnerships across the industry, Spring is at the frontier of antibody development for companion diagnostics, IVD and early clinical markers. Learn more at www.Springbio.com.

For additional information, please contact:
Chris Watts
Spring Bioscience/Caldwell VanRiper Public Relations
(317) 638-9284 or (317) 514-3184
[email protected]